NEW YORK, Jan. 24 (GenomeWeb News) - Organon has secured the cooperation of Shanghai Genomics in the company's program to identify selective steroid hormone receptor modulators, Organon said today.
The research, which represents Organon's second major research project in China, will focus on rheumatoid arthritis, atherosclerosis, and oncology and will last two years, said Organon.
Financial details were not disclosed.
Shanghai Genomics was founded in August 2001. It merged with Tokyo-based Gene Networks International in June 2005.